Kathleen Van Dyk, PhD
Dr. Kathleen Van Dyk's research interests center around cognitive health in cancer survivorship. This includes understanding the mechanisms of cancer-related cognitive impairment, the impact of treatments, cognitive assessment and screening practices and developing strategies and interventions for both assessment and treatment.
Van Dyk K, Crespi CM, Petersen L, Ganz PA. Identifying cancer-related cognitive impairment using the FACT-Cog Perceived Cognitive Impairment. JNCI Cancer Spectrum. [in press]
Van Dyk K, Crespi CM, Bower JE, Castellon SA, Petersen L, Ganz PA. The cognitive effects of endocrine therapy in survivors of breast cancer: A prospective longitudinal study up to 6 years after treatment. Cancer. 2019 Mar 1;125(5):681-689. doi: 10.1002/cncr.31858. Epub 2018 Nov 28.
Carroll JE, Van Dyk K, Bower JE, Scuric Z, Petersen L, Schiestl R, Irwin MR, Ganz PA. Cognitive performance in survivors of breast cancer and markers of biological aging. Cancer. 2019 Jan 15;125(2):298-306. doi: 10.1002/cncr.31777. Epub 2018 Nov 26.
Van Dyk K, Ganz PA, Ercoli L, Petersen L, Crespi CM. Measuring cognitive complaints in breast cancer survivors: psychometric properties of the patient's assessment of own functioning inventory. Support Care Cancer. 2016 Dec;24(12):4939-4949. Epub 2016 Jul 19.
Van Dyk K, Petersen L, Ganz PA. Comparison of Neurocognitive Function After Anthracycline-Based Chemotherapy vs Nonanthracycline-Based Chemotherapy. JAMA Oncol. 2016 Jul 1;2(7):964-5. doi: 10.1001/jamaoncol.2016.0350. No abstract available.